AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis
Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This study will examine how an approved drug (TriLipix), when used in combination with a
statin (a drug that lowers blood cholesterol levels), affects the makeup of plaque. Patients
will be randomly assigned to receive either the study treatment (TriLipix plus Atorvastatin)
or the comparison treatment (a placebo). Comparison of the effect on the makeup of plaque
will be done by using coronary artery computed tomography angiography (CTA), which all
participants will have at enrollment and at the end of the study (18 months after
enrollment).